微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 22.08% | 146.92% | 47.18% | 135/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 15% | -21.59% | 19.74% | 145/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 12.53% | -52.52% | 4.28% | 142/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 12.01% | -53.45% | 34.35% | 144/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 8.94% | -68.59% | -53.26% | 142/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 19.13% | -14.25% | -27.48% | 138/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 26.38% | 2.16% | 2.22% | 123/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 25.81% | -4.84% | -9.34% | 126/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 28.47% | 7.11% | 27.59% | 119/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 22.31% | 7.31% | -13.61% | 135/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 25.83% | 3.1% | -4.78% | 127/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 27.12% | 8.26% | 2.05% | 124/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 26.58% | -11.27% | 27.83% | 123/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 20.79% | -5.85% | -17% | 139/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 25.05% | 6.05% | -0.02% | 124/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 25.05% | 10.67% | -16.36% | 131/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 29.95% | 23.56% | 35.64% | 111/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 22.08% | 87.41% | -6.51% | 141/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 23.62% | 85.63% | 4.33% | 122/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 22.64% | 97.59% | -6.61% | 133/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 24.24% | 42.26% | 105.74% | 112/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 11.78% | -51.72% | -7.4% | 139/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 12.72% | -50.7% | 11.05% | 113/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 11.46% | -51.9% | -32.76% | 124/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 17.04% | -24.83% | -30.18% | 104/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 24.41% | -4% | -5.44% | 123/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 25.81% | 2.35% | 8.35% | 98/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 23.82% | -16.05% | 5.08% | 105/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 22.67% | -27.37% | -10.83% | 97/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 25.42% | 9.36% | 0.81% | 120/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 25.22% | 31.93% | -11.13% | 94/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 28.38% | 37.72% | -9.09% | 92/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 31.21% | 55.45% | 34.27% | 83/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 23.25% | -30.85% | 21.62% | 113/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 19.12% | 2% | -7.23% | 92/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 20.6% | -46.7% | 2.61% | 98/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 20.08% | 2% | -40.27% | 83/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 33.62% | -24.02% | -13.04% | 80/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-06-30 | 38.66% | 2% | -12.63% | 53/157 | 46.26% | 贝达药业 | 95.58% | 行业排名> |